142 related articles for article (PubMed ID: 37011722)
1. Short interfering RNA in colorectal cancer: is it wise to shoot the messenger?
Chandramohan K; Balan DJ; Devi KP; Nabavi SF; Reshadat S; Khayatkashani M; Mahmoodifar S; Filosa R; Amirkhalili N; Pishvaei S; Sargazi-Aval O; Nabavi SM
Eur J Pharmacol; 2023 Jun; 949():175699. PubMed ID: 37011722
[TBL] [Abstract][Full Text] [Related]
2. Novel targeting approaches and signaling pathways of colorectal cancer: An insight.
Tiwari A; Saraf S; Verma A; Panda PK; Jain SK
World J Gastroenterol; 2018 Oct; 24(39):4428-4435. PubMed ID: 30357011
[TBL] [Abstract][Full Text] [Related]
3. Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells.
Silva VR; Santos LS; Dias RB; Quadros CA; Bezerra DP
Cancer Commun (Lond); 2021 Dec; 41(12):1275-1313. PubMed ID: 34791817
[TBL] [Abstract][Full Text] [Related]
4. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
[TBL] [Abstract][Full Text] [Related]
5. Targeting the KRAS, p38α, and NF-κB in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitor.
Zarredar H; Pashapour S; Farajnia S; Ansarin K; Baradaran B; Ahmadzadeh V; Safari F
J Cell Biochem; 2019 Jun; 120(6):10670-10677. PubMed ID: 30656741
[TBL] [Abstract][Full Text] [Related]
6. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
7. Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives.
Fang Z; Meng Q; Xu J; Wang W; Zhang B; Liu J; Liang C; Hua J; Zhao Y; Yu X; Shi S
Cancer Commun (Lond); 2023 Jan; 43(1):3-41. PubMed ID: 36424360
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
[TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements.
Malki A; ElRuz RA; Gupta I; Allouch A; Vranic S; Al Moustafa AE
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374459
[TBL] [Abstract][Full Text] [Related]
10. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
Liu YC; Tsai JJ; Weng YS; Hsu FT
Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
[TBL] [Abstract][Full Text] [Related]
12. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
13. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism.
Ellis BC; Graham LD; Molloy PL
Biochim Biophys Acta; 2014 Feb; 1843(2):372-86. PubMed ID: 24184209
[TBL] [Abstract][Full Text] [Related]
14. Good or not good: Role of miR-18a in cancer biology.
Kolenda T; Guglas K; Kopczyńska M; Sobocińska J; Teresiak A; Bliźniak R; Lamperska K
Rep Pract Oncol Radiother; 2020; 25(5):808-819. PubMed ID: 32884453
[TBL] [Abstract][Full Text] [Related]
15. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
16. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
19. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells.
Huang F; Kao CY; Wachi S; Thai P; Ryu J; Wu R
J Immunol; 2007 Nov; 179(10):6504-13. PubMed ID: 17982039
[TBL] [Abstract][Full Text] [Related]
20. Reg4-induced mitogenesis involves Akt-GSK3β-β-Catenin-TCF-4 signaling in human colorectal cancer.
Bishnupuri KS; Sainathan SK; Bishnupuri K; Leahy DR; Luo Q; Anant S; Houchen CW; Dieckgraefe BK
Mol Carcinog; 2014 Feb; 53 Suppl 1(0 1):E169-80. PubMed ID: 24151146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
